CME-Directory

Start Date: 05/15/2011
End Date: 05/18/2011

City: Lousville
State: KY

Radiation Oncology Board Reviews for written and oral examinations. Live, MP3 audio, and pre-loaded MP3 player formats are available. Live programs only are eligible for up to 30 to 40 hours of Radiation Oncology CME credit for each program. Cost is approximately $300 to $960.

Start Date: 02/01/2011
End Date: 02/01/2014

Take a break from the drudgery of typical Hematology-Oncology CME presentations withTerra Derma, the Online Oncology CME arcade game! .Good up to to 9 Oncology CME credits and approximately FREE.

This activity is presented by Physicians’ Education Resource in conjunction with the University of California, Davis Cancer Center and the support of community oncologists from diverse practices within Northern California (Kaiser Permanente, Sacramento Center for Hematology and Medical Oncology, Capitol Hematology Oncology, and Sierra Hematology Oncology). For the past nine years, the annual Advances in Oncology symposium has provided a unique educational opportunity for physicians in the Greater Sacramento and Northern California area. The 10th Annual Advances in Oncology program will once again bring together academic and community physicians for the purpose of educating participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Furthermore, the timing of this meeting in September allows for the latest findings in clinical cancer research from major international oncology conferences to be presented. This symposium has been designed to update physicians on recent advances and new diagnostic and treatment modalities in the management of hematologic, colorectal, lung, genitourinary, and breast cancers. This symposium also meets a unique need for the Northern Sacramento Valley to provide a group of networked and collaborating oncologists to exchange and apply recent developments in oncology in the context of local treatment approaches, patient populations, referral patterns, and open clinical trials. This is reflected in the format providing ample time for panel discussions that involve a large array of local practicing oncologists. The program will include didactic sessions from leading faculty followed by extensive interactive case-based panel discussions involving community-based physicians to discuss solutions to clinical challenges that physicians face in their daily practice. The knowledge transmitted through this program, together with partnerships with UC Davis physicians, will improve cancer care for patients in the Northern California region. Additional CME Accreditation and Credit Designation Information Registered Nurse: The California Board of Registered Nursing accepts AMA PRA Category 1 CreditsTM toward license renewal. On the BRN license renewal form, report the number of hours you attended (up to XX hours of credit) and fill in “CME Category 1” for the provider number. California AB 1195: This activity complies with California Assembly Bill 1195, signed November 2005, requiring continuing medical education courses with patient care components to include curricula in the subject of cultural and linguistic competency. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. Target Audience This educational program is directed toward medical, radiation, and surgical oncologists with an interest in recent advances in the treatment of solid tumors as well as hematologic malignancies. Fellows, oncology nurses, oncology physician assistants, and pharmacists are also invited to attend. Learning Objectives At the conclusion of this symposium you should be able to: Discuss prognostic and predictive biomarkers and potential applications in therapeutic decision making Integrate targeted and traditional therapeutic modalities in the treatment of cancer Assess newly validated treatment options for patients with solid tumors or hematologic malignancies Apply data from clinical trials to determine the optimal course of therapy in defined patient populations

The purpose of the 10th International Lung Cancer Congress is to update participants on advances in lung cancer, including biology, pathology, staging, individualized therapy, novel agents, and supportive care. The congress will discuss current trends in surgical, radiotherapeutic, and chemotherapeutic approaches to lung cancer and will provide a perspective on clinical data presented at major international oncology meetings. An ongoing focus will be the individualization of therapy based on clinical, histologic, and molecular characteristics. Areas of controversy in lung cancer therapy, including treatment of early-stage and locally advanced disease, testing for molecular markers, and the optimal combination of targeted and cytotoxic agents will be the subject of panel discussions and debates. The congress will also feature presentations on optimizing the application of established targeted agents as well as presentations introducing emerging targeted agents, including mechanisms of action and clinical/preclinical results. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups in the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, and question-and-answer sessions as well as afternoon translational workshops focusing on strategies currently in development for the treatment of lung cancer. This educational program is directed toward medical oncologists, radiation oncologists, thoracic surgeons, and pulmonologists as well as investigators, practitioners, and fellows in training with research interests in lung cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. Nurses, physician assistants, and other individuals interested in the treatment of lung cancer are also invited to attend.

The purpose of the 11th International Lung Cancer Congress is to provide participants with an update on advances in the field of lung cancer, including biology, pathology, staging, personalized therapy, maintenance therapy, novel agents, and ongoing research in Cooperative Groups. Bringing key data from international oncology conferences to participants, the congress will emphasize the importance of personalized therapy and address other current topics of interest, such as maintenance therapy and novel targeted agents. State-of-the-art treatment for early-stage locally advanced and metastatic lung cancer will be discussed. In addition to non–small-cell lung cancer (NSCLC), the congress will address therapy for small-cell lung cancer (SCLC) and mesothelioma. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups from the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, question-and-answer sessions, and afternoon translational workshops focusing on future strategies in development for the treatment of lung cancer

Start Date: 02/11/2011
End Date: 02/11/2014

Practical Reviews in Nuclear available in MP3, Audio CD, and Multimedia Online. Good up to 48 Nuclear Medicine CME credits. Cost is approximately $299 to $599.

Overview and Purpose The 12th International Lung Cancer Congress is designed to provide participants with an update on advances in lung cancer research and therapy, including biology, pathology, screening, staging, personalized therapy, maintenance therapy, novel agents, and ongoing research in Cooperative Groups. Bringing key data from international oncology conferences to participants, the congress will emphasize the importance of personalized therapy and address other current topics of interest. State-of-the-art treatment for early-stage locally advanced and metastatic lung cancer will be discussed. In addition to non–small-cell lung cancer (NSCLC), the congress will address therapy for small-cell lung cancer (SCLC) and mesothelioma. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups from the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, question-and-answer sessions, and afternoon translational workshops focusing on future strategies in development for the treatment of lung cancer. Target Audience This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend. Learning Objectives At the conclusion of this congress, you should be able to: Evaluate the role of CT screening for early detection of lung cancer Discuss the role of pulmonologists in the diagnosis of and treatment selection for patients with lung cancer Appraise clinical data on adjuvant chemotherapy in patients with early-stage NSCLC Evaluate the efficacy and toxicity of combined modality regimens in locally advanced NSCLC Optimize therapy for patients with metastatic NSCLC based on biomarker status and tumor characteristics Discuss the clinical benefits of maintenance therapy in advanced NSCLC Personalize therapeutic approaches for patients with mesothelioma Describe current approaches to patients with limited- and extensive-disease SCLC Discuss clinical data on new targeted agents in development for lung cancer Summarize current research activity in lung cancer from national and regional Cooperative Groups

Held in Conjunction With the 10th Annual Medical Oncology Fellows Forum Important advances in the field of oncology over the last several years have led to improvements in outcome for several malignancies and newer options for refractory disease. This has resulted in a need to improve performance in clinical practice through the understanding of how to optimally individualize care based on benefits and risks in specific situations and defined patient populations. The 13th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine has been designed to address clinical challenges and practical issues faced each day by community oncologists, oncology nurses, oncology physician’s assistants and other oncology professionals. The conference is intended to inform oncology professionals and fellows in training of the recent data on agents approved for and being evaluated in the most common tumor types, including breast, lung, genitourinary, gastrointestinal, gynecological and hematologic malignancies, and sarcoma. In addition, this activity focuses on providing a thorough understanding of the toxicity profiles of controversial and evolving regimens with hormonal therapy, chemotherapy, and novel targeted agents so as to aid oncology professionals in making effective decisions regarding treatment, management of patients and trial enrollment.

The 15th Annual International Congress on Hematologic Malignancies provides a unique opportunity for medical oncologists, hematologists, and other health care professionals to learn from and interact with international leaders in the field of hematologic malignancies in order to integrate current clinical data into individualized treatment plans for improved patient care. Educational opportunities include: Lectures on state-of-the-art therapy by disease Multidisciplinary case discussions Workshop sessions on emerging agents “Meet-the-Professor” breakfasts

Over the past decade, an increasing number of oncologists have concentrated their practices on breast cancer. In order to advance patient care, the School of Breast Oncology was developed. This curriculum-based program focuses exclusively on breast cancer clinical management. The intensive 4-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment. The curriculum will be evidence based, summarizing the existing data for each topic and applying these data to patient cases.

The 28th Annual Miami Breast Cancer Conference™ provides a unique opportunity for medical oncologists and other health care professionals to learn from and interact with international leaders in the field of breast cancer in order to increase knowledge, apply new data to practice, and ultimately improve patient outcomes.

The optimal care of patients with breast cancer is rapidly changing as a result of advances in all aspects of patient care, including prevention, screening, and detection, as well as in the primary treatment modalities of surgery, radiation therapy, endocrine therapy, cytotoxic chemotherapy, and novel biologic therapies. There is an increasing focus on providing multidisciplinary care for patients with complex diseases such as breast cancer through the use of integrated teams of professionals representing the relevant treatment modalities, including surgery, radiation therapy, and systemic medical interventions. The multidisciplinary Miami Breast Cancer ConferenceTM has been bringing together surgical, medical, and radiation oncologists for 29 years, with the aim of fostering awareness of the state-of-the-art treatments in each therapeutic area and encouraging cross-team cooperation in the clinic. At the 29th Annual Miami Breast Cancer Conference, pioneers of innovative approaches in each of these subspecialties will provide insight into the optimal multidisciplinary management of patients with breast cancer and its application to practice.

During this three and a half day conference, you will benefit from an intimate learning environment where renowned faculty will present the latest in oncology care. In addition to the rich educational program, you will appreciate the venue’s comfort and exceptional service, along with a well organized format allowing for ample free time to enjoy San Diego’s many charms.

This course is designed for oncology nurse practitioners and clinical nurse specialists, as well as other advanced practice professionals interested in innovative oncology care. The purpose is to update the health care professional on clinical issues and current trends in cancer practice.

For Additional Information Scripps Conference Services & CME Email med.edu@scrippshealth.org Phone 858-652-5400 Fax 858-652-5565 Visit www.scripps.org/conferenceservices

Chair: Jean Klastersky, MD

Chairs: Mario Dicato, MD and Eric van Cutsem, MD Abstract Deadline: 24 February 2006

Start Date: 02/01/2011
End Date: 02/01/2014

Description: Take a break from the drudgery of typical Hematology-Oncology CME presentations with AML Tour, the Online Oncology CME arcade game! This Online Hematology-Oncology CME arcade game is good for up to 9 Oncology CME credits and this is absolutely FREE.

The Annual Community Oncology Research Forum brings together academic and community physicians as well as oncology nurses and physician assistants in order to update participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Lectures will highlight current standards, cutting-edge information, and emerging treatment strategies for specific tumor types, followed by new clinical trial designs and patient case-based panel discussions on practical disease management. Other sessions will focus on key biologic mechanisms in cancer development as well as the ethics of clinical trials and biomedical statistics as they pertain to clinical trial design and interpretation. This meeting presents an opportunity for continuous dialogue and interaction between academic thought leaders and community oncologists.

Start Date: 02/01/2011
End Date: 02/01/2014

Oncology CME Audio updates covering the latest in clinical diagnosis and treatment of cancer. These audio reviews are delivered monthly, available online as MP3, or via mail as audio CD for up to 24 hours of oncology CME credit annually. Cost is approximately $359 to $479.

The Role of Gastroenterologists, Surgical Oncologists, and Medical Oncologists in the Care of Patients with GIST: Diagnosis, Monitoring, and Referral; Considerations on Resection and Adjuvant Therapy; How should Pharamacologic Agents be Incorporated into the Current Treatment Landscape?

Saving the Hearts of Women: This CME course is designed to provide practical guidelines for management of the range of cardiovascular diseases in women, including coronary heart disease, arrhythmias and valvular disease with particular attention to racial and ethnic differences. An additional segment will focus on answering many other questions asked by patients, including the role of stress and depression in heart disease and the role of hormones and vitamin supplements in the prevention of heart disease. A final segment will address the potential for cardiotoxcity in breast cancer patients receiving chemotheraphy and in survivors. Through lectures, case management discussions and open question and answers, expert faculty practical information that attendees can use in their daily practice. 4th Annual Breast Cancer Update Including New Data from the San Antonio Breast Meeting: This course synthesizes the scope of breast cancer research and shows how to apply the rapid transition of new knowledge into improved care for breast cancer patients. Through lectures, case management discussions and open question and answers, expert faculty provide practical information that attendees can use in their daily practice.

The Changing Paradigms in T-Cell Lymphomas satellite symposium is designed to provide community oncologists who treat patients with T-cell lymphomas with practical, multidisciplinary approaches that can be applied immediately to their clinical practice. This program will include expert commentary outlining the essentials of T-cell lymphoma histopathology and the most current therapeutic approaches to both peripheral and cutaneous T-cell lymphomas. Tumor board sessions will provide an opportunity to reinforce best practices in diagnosis and treatment and provide an insight into how experts manage cases when clinical data are lacking. Debate and audience questions and comments will add to the interactive nature of this program. Target Audience This educational program is directed toward medical oncologists and hematologists interested in the treatment of patients with T-cell lymphoid malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of T-cell lymphomas are also invited to attend. Learning Objectives At the conclusion of this symposium, you should be able to: Discuss the histopathologic features of the various PTCL and CTCL lymphoma entities Evaluate current treatment options and strategies for adverse events in patients with PTCL and CTCL Appraise the efficacy and safety of emerging treatment strategies for patients with CTCL and PTCL Evaluate the role of new combinations and new agents in the continuum of care for patients with T-cell lymphomas Meeting information is accurate at the time of posting.